{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:27:06Z","timestamp":1784903226198,"version":"3.55.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/infdis\/jiz245","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T22:48:47Z","timestamp":1557269327000},"source":"Crossref","is-referenced-by-count":15,"title":["Baloxavir and Treatment-Emergent Resistance: Public Health Insights and Next Steps"],"prefix":"10.1093","author":[{"given":"Larisa V","family":"Gubareva","sequence":"first","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia M","family":"Fry","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,16]]},"reference":[{"key":"2019073013201590600_CIT0001","author":"Infectious Diseases Society of America"},{"key":"2019073013201590600_CIT0002","author":"U.S. Department of Health and Human Services"},{"key":"2019073013201590600_CIT0003","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","article-title":"Influenza virus polymerase inhibitors in clinical development","volume":"32","author":"Hayden","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"2019073013201590600_CIT0004","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.coviro.2016.05.004","article-title":"Current and novel antiviral strategies for influenza infection","volume":"18","author":"Yen","year":"2016","journal-title":"Curr Opin Virol"},{"key":"2019073013201590600_CIT0005","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiz244","article-title":"Treatment emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza","author":"Uehara","year":"2019","journal-title":"J Infect Dis"},{"key":"2019073013201590600_CIT0006","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"2019073013201590600_CIT0007","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci Rep"},{"key":"2019073013201590600_CIT0008","article-title":"Identification of the I38T PA substitution as a resistance marker for next-generation influenza virus endonuclease inhibitors","volume":"9","author":"Jones","year":"2018","journal-title":"MBio"},{"key":"2019073013201590600_CIT0009","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy775","article-title":"Influenza vaccine effectiveness in the United States during the 2016\u20132017 Season","author":"Flannery","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2019073013201590600_CIT0010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.antiviral.2011.11.006","article-title":"The 2008\u20132009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses","volume":"93","author":"Wu","year":"2012","journal-title":"Antiviral Res"},{"key":"2019073013201590600_CIT0011","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1098\/rsif.2011.0427","article-title":"The global spread of drug-resistant influenza","volume":"9","author":"Chao","year":"2012","journal-title":"J R Soc Interface"},{"key":"2019073013201590600_CIT0012","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antiviral Res"},{"key":"2019073013201590600_CIT0013","author":"National Institute of Infectious Diseases"},{"key":"2019073013201590600_CIT0014","article-title":"Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019","volume":"24(12):1900170","author":"Takashita","year":"2019","journal-title":"Euro Surveill"},{"key":"2019073013201590600_CIT0015","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S1473-3099(17)30476-0","article-title":"Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Beigel","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2019073013201590600_CIT0016","doi-asserted-by":"crossref","first-page":"e29778","DOI":"10.1371\/journal.pone.0029778","article-title":"Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus","volume":"6","author":"Hoopes","year":"2011","journal-title":"PLoS One"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiz245\/29019925\/jiz245.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T14:39:33Z","timestamp":1569249573000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiz245\/5532608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,16]]},"references-count":16,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz245","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,16]]},"article-number":"jiz245"}}